Indeed, regardless of the aforementioned considerations about the effective pathway and transporter involved in tubulo-glomerular feedback following sodium-glucose cotransporter-2 inhibitors, it remains unclear whether these renal hemodynamic changes can explain all the benefits of SGLT2i and the nephroprotection whatever the type of diabetes: type 1 or 2. Here, SLC5A2 is linked to diabetes mellitus.